APUS vs OKTA · $2.4M cap vs P/E 84, rev $1.57B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
APUS does not have a complete income-statement cache yet.
Latest reported OKTA revenue for 2026-07-31 was $1.57B. Net income was $190.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
APUS currently screens at market cap $2.4M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the APUS and OKTA stock pages for the full models.
Not investment advice.